Incremental value of C-reactive protein to the MEESSI acute heart failure risk score

Desiree Wussler1,2, Maria Belkin1,2, Samyut Shrestha1,2

  • 1Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel, Basel, Switzerland.

Insights

Adding C-reactive protein (CRP) to the MEESSI score improves acute heart failure (AHF) risk stratification. This enhanced model better predicts 30-day mortality and identifies more low-risk patients.

Area of Science:

  • Cardiology
  • Clinical Risk Stratification
  • Inflammation Biomarkers

Background:

  • Acute heart failure (AHF) poses significant mortality risks.
  • Current risk stratification models, like the MEESSI-AHF score, are crucial for patient management.
  • The role of systemic inflammation in AHF prognosis requires further investigation.

Purpose of the Study:

  • To enhance the MEESSI-AHF risk score by incorporating C-reactive protein (CRP) levels.
  • To evaluate the incremental value of CRP in predicting 30-day mortality in AHF patients.
  • To assess the impact of CRP addition on risk stratification accuracy and clinical usefulness.

Main Methods:

  • Prospective multicentre diagnostic study (BASEL V) with central adjudication of AHF cases.
  • Calculation of the established MEESSI-AHF risk score using 12 independent risk factors.
  • Logistic regression model extension by adding CRP to assess 30-day mortality, with validation in an independent cohort.

Main Results:

  • The extended MEESSI model incorporating CRP showed significantly higher prognostic accuracy (c-statistic 0.83) compared to the original model (c-statistic 0.79).
  • The enhanced model stratified a greater percentage of patients into the lowest risk group (33.1% vs. 20.3%).
  • Excellent and improved calibration was demonstrated, with results confirmed in an independent validation cohort.

Conclusions:

  • Quantifying systemic inflammation via CRP concentration offers incremental value to the MEESSI model for AHF risk stratification.
  • The addition of CRP improves the accuracy and clinical utility of risk assessment in AHF patients.
  • The findings support the integration of inflammatory markers into existing AHF risk prediction tools.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
76
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
136
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419